Predict your next investment

OCON Medical company logo
HEALTHCARE | Medical Devices & Equipment / Other Medical Devices
oconmed.com

See what CB Insights has to offer

Founded Year

2011

Stage

Seed VC - II | Alive

Total Raised

$3.68M

About OCON Medical

OCON Healthcare develops, manufactures, and commercializes cutting-edge women’s health products based on its patented IUB (Intra Uterine Ball) proprietary platform. The IUB, made from a super-elastic alloy Nitinol, is an ideal carrier for multiple drugs to the uterus to treat a variety of conditions.

OCON Medical Headquarter Location

Hamiktso’ot Blvd. 14 15 Hashdera Hamerkazit

Modi'In, 7178095,

Israel

+972 72 21 50 105

Latest OCON Medical News

IUB Ballerine: an ergonomic approach to non-hormonal contraception

Jun 16, 2021

By Chloe Kent 16 Jun 2021 (Last Updated June 16th, 2021 13:06) IUB Ballerine is reinventing the non-hormonal intrauterine device for the 21st century. Credit: Shutterstock Share Article Finding a suitable contraceptive isn’t always a straightforward process. The number of options available can often seem overwhelming, and each comes with a catalogue of potential side effects and different levels of efficacy, all of which needs to carefully considered before a decision is made. Hormonal forms of contraception, such as the pill or the implant, tend to work by stopping the body from ovulating using synthetic versions of the hormones that people already naturally produce. However, they have been linked to a wide range of side effects, including acne, mood swings and even rare cases of blood clots , which many patients find off-putting. For those who prefer a non-hormonal option, the copper intrauterine device (IUD) is an increasingly popular choice and is known to be 99% effective in preventing pregnancy. The small, T-shaped piece of plastic and copper doesn’t prevent ovulation but is inserted into the uterus for five to ten years, and acts as a spermicide. The increased copper ions within the cervical mucus damage sperm and disrupt their motility, making it difficult for them to fertilise an egg. It is also thought that should an egg still become fertilised, the copper IUD may prevent the fertilised egg from implanting into the uterine wall. However, this mechanism of action is contested and there has been no concrete evidence that IUD users experience higher levels of embryonic loss compared to those not using contraception. The non-hormonal IUD may leave the body’s natural hormonal balance unaffected, but it can still lead to complications. The most common side effect is heavier and more painful menstrual periods, which occurs in 20% to 50% of users. Rarer, more serious complications can arise as well. IUDs have been known to expel themselves from the uterus, a complication thought to arise in 2.2% to 11.4% of cases, as well as perforate the uterine lining – something which only happens 0.3% to 2.6% of the time but can be very serious when it does. The copper IUD can also become malpositioned within the uterus, with one study finding that 11% of IUDs became malpositioned . This is typically associated with significant pain and excess bleeding, although some people will find it doesn’t cause them any problems. Additionally, on the rare occasions a pregnancy does occur in an IUD user, it’s more likely to be ectopic, implanting outside of the womb. These pregnancies are not viable and usually need to be removed either medically or surgically. Now, the team at OCON Medical say they’ve come up with a solution to these complications. Meet the IUB Ballerine OCON’s intrauterine ball (IUB Ballerine) first launched in Austria in 2014, works along the same principle as the T-shaped copper coil, preventing pregnancy by releasing copper ions into the uterus. Like some copper IUDs, it can be left in place for five years and is also 99% effective in preventing pregnancy. But where the traditional IUD is rigid and sharp, potentially leading to discomfort or pain, the IUB is made up of 17 small copper beads strung along a flexible string made of a metal called nitinol. Nitinol, an alloy used extensively in medical implants such as coronary stents, can be programmed to retain a certain shape, and here is designed to curl up into a ball. During insertion, the string is stretched out to allow it to pass through the cervical opening and into the uterus, but it springs back into a ball shape when the procedure is complete. The IUB Ballerine is also a fraction of the size of a standard IUD, measuring 15mm in diameter compared to up to 32mm in diameter for T-shaped devices. OCON Medical CEO Keren Leshem says: “It may sound obvious, but the uterus is not two-dimensional. It’s a three-dimensional cavity with constant contractions which present issues when 2D intrauterine carriers are located within. “Due to the IUB Ballerine’s spherical 3D shape, smaller size and its flexible frame, it fully adapts to the shape and contractions of the uterine cavity, causing less irritation to the lining of the uterus. Having a ball-shape means it cannot malposition – a ball will always be a ball no matter which way it turns.” In theory, the IUB should work more ergonomically with the body than the IUD, leading to fewer unpleasant side effects while retaining the same efficacy. As well as reducing the risk of malpositioning, the risk of perforation should be reduced too – the IUB lacks any sharp edges that could pierce the uterine wall. Leshem says: “The Ballerine has built-in safety mechanisms turning it 180° away from the upper uterine wall upon release inside the cavity, leading to less perforation risk. “Additionally, there is a tremendous safety advantage when looking at ectopic pregnancies. The small ball inside the cavity does not block the entrance of the fallopian tubes like the T-IUD does, resulting in a 90% reduction in the risk of a pregnancy developing outside the uterine cavity. Almost 50% of pregnancies that occur with traditional IUDs are ectopic.” OCON estimates that of the over 100,000 IUB Ballerine insertions to date, expulsion rates are around 3.5%, perforation 0.07% and ectopic pregnancy only 0.01%. What is next for OCON Medical? OCON says that the basic design of IUB Ballerine can be repurposed for a number of indications and that it is currently researching and developing several treatment options for uterine health issues. These include abnormal uterine bleeding, heavy menstrual bleeding, uterine fibroids and cancers, endometriosis and hormonal replacement therapy. The company is also looking into developing a hormonal contraceptive version of the IUB Ballerine, to give users additional options. It is currently undergoing Phase II clinical trials into the IUB Spherical Endometrial Ablation Device (SEAD), an intrauterine drug delivery system for people with abnormal uterine bleeding or heavy menstrual being. “The IUB SEAD is a market game-changer through simplicity, cost-effectiveness and new and innovative yet gentle ‘substance-derived ablation’ technology,” says Leshem. “The current standard of care, global endometrial ablation, is considered invasive, burdensome, debilitating, costly and may result in uterine wall adhesions and even a hysterectomy. Current global ablation technologies currently in use require expensive capital equipment, extensive physician training, general anaesthesia and hospitalisation and cause high indirect costs and usually pain to women.” OCON is also looking to roll out the IUB Ballerine into more territories. It is currently available in numerous European territories, as well as Israel, Kenya, Uganda and South Africa, and OCON is planning to expand to South America, Russia and the Commonwealth of Independent States, Ukraine, Japan and Turkey. While the Ballerine was supposed to become available on the UK NHS last year, the rollout was delayed as a result of the Covid-19 pandemic. It is however available privately. Leshem says: “OCON will continue to lead with excellence in the FemTech space. We see OCON becoming a hub for women’s health by building pillars of therapies all directed to conditions currently treated systemically, using pills with side effects. “Now women will be able to treat conditions such as abnormal uterine bleeding, endometriosis, myomas, cancers and other indications directly at the target tissue with safe and effective technology that fit their anatomy.” Related Companies

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing OCON Medical

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

OCON Medical is included in 2 Expert Collections, including Medical Devices.

M

Medical Devices

7,401 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. Excludes CDMOs/CMOs. *Columns updated as regularly as possible.

W

Women's Health & Wellness

947 items

Startups focused on providing products and services catering to women's health and wellbeing.

OCON Medical Patents

OCON Medical has filed 5 patents.

The 3 most popular patent topics include:

  • Dosage forms
  • Drug delivery devices
  • Gynaecology
patents chart

Application Date

Grant Date

Title

Related Topics

Status

12/11/2014

2/2/2021

Dosage forms, Drug delivery devices, Hormonal contraception, Gynaecology, Women's health

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

12/11/2014

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Grant Date

2/2/2021

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

Dosage forms, Drug delivery devices, Hormonal contraception, Gynaecology, Women's health

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

OCON Medical Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

OCON Medical Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.